Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics
Roche's Q1 2026 sales grew 6% at constant exchange rates, driven by strong demand for innovative medicines, particularly in multiple sclerosis and oncology.
Therapeutic Area
Therapeutic area intelligence for Diagnostics and Multiple Sclerosis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.